Rizatriptan Benzoate Tablet
Product Images NDC 51407-681

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 51407-681). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-681-12 Ct (pl).jpg (51407 681 12 Ct (pl))

Box carton label for Rizatriptan Benzoate Tablets USP 5 mg by Golden State Medical Supply, Inc. The package contains 12 tablets (4 blister cards of 3 tablets each). The label includes storage instructions, a barcode, child-resistant packaging note, and marketing information indicating the product is made in India and marketed by GSMS, Incorporated.*

FDA Label Image

51407-682-12 Ct (pl).jpg (51407 682 12 Ct (pl))

Packaging label for Rizatriptan Benzoate Tablets, USP 10 mg oral tablets. The box indicates the package contains 12 tablets in 4 blister cards of 3 tablets each. Labeler is Golden State Medical Supply, Inc. The label features dosage information, storage instructions, a barcode, and notes that the package is child-resistant.*

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

A line graph titled 'Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4' showing estimated probability of response on the y-axis (0%-100%) and hours post-dose on the x-axis (0 to 2 hours). The graph compares placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg, with response probabilities increasing over time, highest for the 10 mg dose.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Po (Rizatriptan Fig2)

Kaplan-Meier plot showing the estimated probability over 24 hours of patients taking a second dose of Rizatriptan Benzoate tablets (5 mg and 10 mg) or other medication for migraines after the initial dose, compared with placebo. The y-axis represents estimated probability of remediation or rescue, and the x-axis shows hours post-dose from 0 to 24.*

FDA Label Image

Figure3 (Rizatriptan Fig3)

A line graph illustrating the percentage effect over time comparing Rizatriptan Benzoate orally disintegrating tablets to placebo. The x-axis represents hours post stage 2 dose (0.5 to 2.0 hours), and the y-axis shows percentage with 95% confidence intervals. The graph shows Rizatriptan Benzoate tablets with a higher percentage response than placebo over time.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical structure of Rizatriptan Benzoate shown as two connected molecular diagrams. One depicts the triptan core structure, and the other shows the benzoate moiety with a carboxyl group attached to a benzene ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.